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Abstract: Background: Numerous epidemiological studies indicated high levels of particulate matter
less than2.5 µm diameter (PM2.5) as a major cardiovascular risk factor. Most of the studies have been
conducted in high-income countries (HICs), where average levels of PM2.5 are far less compared
to low- and middle- income countries (LMICs), and their socio-economic profile, disease burden,
and PM speciation/composition are very different. We systematically reviewed the association of
long-term exposure to PM2.5 and cardio-metabolic diseases (CMDs) in LMICs. Methods: Multiple
databases were searched for English articles with date limits until March 2018. We included studies
investigating the association of long-term exposure to PM2.5 (defined as an annual average/average
measure for 3 more days of PM2.5 exposure) and CMDs, such as hospital admissions, prevalence,
and deaths due to CMDs, conducted in LMICs as defined by World Bank. We excluded studies
which employed exposure proxy measures, studies among specific occupational groups, and specific
episodes of air pollution. Results: A total of 5567 unique articles were identified, of which only 17
articles were included for final review, and these studies were from Brazil, Bulgaria, China, India,
and Mexico. Outcome assessed were hypertension, type 2 diabetes mellitus and insulin resistance,
and cardiovascular disease (CVD)-related emergency room visits/admissions, death, and mortality.
Largely a positive association between exposure to PM2.5 and CMDs was found, and CVD mortality
with effect estimates ranging from 0.24% to 6.11% increased per 10 µg/m3 in PM2.5. CVD-related
hospitalizations and emergency room visits increased by 0.3% to 19.6%. Risk factors like hypertension
had an odds ratio of 1.14, and type 2 diabetes mellitus had an odds ratio ranging from 1.14–1.32.
Diversity of exposure assessment and health outcomes limited the ability to perform a meta-analysis.
Conclusion: Limited evidence on the association of long-term exposure to PM2.5 and CMDs in the
LMICs context warrants cohort studies to establish the association.
Keywords: air pollution; cardio-metabolic diseases
1. Background
Cardiovascular disease (CVD) is the leading cause of death in nearly all countries around the
globe [1], and chronic exposure to air pollution is an important risk factor for CVD. Based on numerous
epidemiological studies, particulate matter with a diameter of less than 2.5 micrometers (PM2.5)
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is considered to be the main culprit for these adverse cardiovascular effects [2–4]. Evidence from
systematic reviews and meta-analyses suggests a strong association between short-term exposure
to elevated PM2.5 and hospital admissions, myocardial infarction, stroke, and heart failure [5–8].
Even in countries where current international air quality standards are met (i.e., the World Health
Organization (WHO) standards of 10 µg/m3 annual mean concentration or 25 µg/m3 24-hour mean
concentration) [2,9–12], small increases in PM2.5 are associated with increased risk of stroke [13].
More recent evidence suggests that chronic, i.e., long-term exposure to elevated PM2.5 also
contributes substantially to cardio-metabolic diseases (CMDs) [4,14]. A meta-analysis from European
and North American studies reported that the association between PM2.5 and type 2 diabetes mellitus
(T2DM) increased the risk by 10% for every 10 µg/m3 increase in PM2.5 [15], which was similar to a
meta-analysis conducted in 2014 that found an 11% increase in T2DM risk per 10 µg/m3 increase in
PM2.5 among five identified studies [16]. Similarly, a systematic review conducted in 2015 identified
five studies on long-term PM2.5 exposure and hypertension risk, and meta-analysis revealed a small
albeit statistically non-significant effect summary odds ratio (OR) = 1.06 (95% confidence interval (CI),
0.98, 1.15) [17]. All of these reviews included only developed countries (US, Canada, and Europe).
Thus, while an association between PM2.5 and CMD has been demonstrated by epidemiological
studies conducted in developed countries, where the annual average PM2.5 concentrations are near
the WHO standard, scientific evidence from low- and middle-income countries (LMICs) is extremely
limited [18]. This is concerning given substantially higher exposure levels in LMICs due to rapid
industrialization and inadequate enforcement of environmental regulations [19]. Moreover, differences
in the sources and composition of ambient air pollution, diet, and chronic disease status limit the
generalizability of findings from developed countries [20]. To further define the current state of the
science in LMICs, we conducted a systematic literature review of the association between long-term
exposure to PM2.5 and CMDs in LMICs.
Objective
To systematically compile evidence for the association between long-term exposure to PM2.5 and
CMDs in LMICs.
2. Materials and Methods
We performed this study in three stages: database search, title and abstract screening, and
full-text review and extraction. First, we searched the following databases: Medline and Embase (from
January 1, 1948 to March 6, 2018), Cumulative Index to Nursing and Allied Health Literature, SCOPUS,
Cochrane database, and Web of Science. We restricted our search to articles published in English, and
we only considered peer-reviewed original articles. Detailed search terms are provided in Appendix A.
3. Definitions
For the purpose of this review, we defined CMDs as a clustering of disorders (hypertension, lipid
disorders, hyperinsulinemia, and glucose intolerance) that together lead to CVD and T2DM [21,22].
We focused specifically on long-term exposure to PM2.5, defined as an annual average or average
measure of more than 3 days of PM2.5 exposure. We chose to focus on long-term exposure, given that
the diseases of interest (CMDs) are chronic diseases that develop over long periods of time.
3.1. Inclusion and Exclusion Criteria
We included studies that:
(1) Were original research published in peer-reviewed journals up to March 6, 2018.
(2) Were conducted in an LMIC according to current World Bank classification [23].
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(3) Quantified the association between exposure to PM2.5 and at least one CMD, including
CVD, T2DM, lipid disorders, hypertension, hyperinsulinemia, and glucose intolerance, and
related hospitalizations.
(4) Involved long-term exposure to PM2.5 (annual average or more than 3 days).
We excluded studies that:
(1) Were conducted only among the population aged less than 18 years.
(2) Used proxy measures to assess the exposure to PM2.5 (e.g., proximity to major roads).
(3) Focused on a specific population (e.g., patients with previous CVD events or T2DM).
3.2. Selection of Studies
The search strategy followed the PICO-population, intervention/exposure, comparator (there was
no comparator in our review) and outcomes process [24]: population-general population from LMICs,
intervention/exposure- long-term exposure to PM2.5, and outcomes - CMDs. Titles and abstracts
were screened by three researchers (S.J., G.K.W., and M.M.). A full-text review was then performed
independently by three researchers (S.J., G.K.W., and M.M). Disagreements were resolved by discussion
in a small working group (S.J., G.K.W., M.M., and L.M.J.). Studies were then appraised for quality
using the Cochrane Risk of Bias tool [25]. Each study was assessed for the following: selection bias,
assessment of exposure and outcome, and adjustment for confounders. The studies were classified
into three groups: high-quality (low risk of bias), medium-quality (unclear), and low-quality (high risk
of bias). Two reviewers (S.J. and G.K.W.) independently appraised the studies, and disagreements
were resolved in a consensus meeting. Only high-quality studies were included in this review.
3.3. Data Extraction
Data were extracted using a standardized extraction table that was piloted for two articles.
Data extraction was performed by one researcher (S.J.) and was checked for accuracy by a small
working group (G.K.W., M.M., and L.M.J.). The data extraction included study characteristics (author,
year of publication, year of data collection, region, country, sampling method, sample size, location,
setting), demographics (sex and age distribution), air pollution exposure information (method of
measurement, length of exposure, and average measure), CMDs (prevalence/admissions/mortality,
source of information), and results.
4. Results
4.1. Study Selection Process
We identified 10,861 articles in the database search, of which 5,291 were excluded as duplicates
(Figure 1). Title and abstracts were screened, and 45 studies were identified for full-text review.
Twenty-eight articles were excluded mainly because they were not original research (n = 8), did not
assess PM2.5 (n = 3), assessed short-term PM2.5 exposure (n = 11), did not measure an association
(n = 1), used proxy measures of PM2.5 exposure (n = 1), or were in patients with a pre-existing condition
(n = 4). The final review included 17 studies (Tables 1 and 2).
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Table 1. Study characteristics, exposure, outcome, and primary results of included studies (n = 11, listed alphabetically) measuring PM2.5 exposure less than the
annual average.
Citation Place ofStudy
Study
Period Study Design
Study Population
(Age, Gender) Sample Size
Particulate Matter
Measuring Less Than
2.5 µm (PM2.5)
Measurement
Method
Mean
PM2.5
µg/m3
Exposure
Association to
Outcome
(No. of Days
Exposure Data-
Available)
Outcomes
(Source) Results
[27] Mexico City 1993–1995 Time-seriesstudy
Residents aged 65
years and above 4129
Monitoring station with
24-hour integrated
particle mass
27 4 days (941 days)
Daily mortality
(Electronic
records)
Every 10 µg/m3 increase
in PM2.5 was associated
with a 3.4% (95%
confidence interval (CI)
0.67, 6.18) increase in
cardiovascular disease
(CVD) mortality
[28] Plovdiv,Bulgaria 2014
Cross-sectional
survey
General
population aged
18 years and
above
513 Official municipalitysource 66.8
Not Available
(NA) (150 days)
Type 2 diabetes
mellitus (T2DM)
prevalence
(survey)
T2DM was positively
associated with PM2.5 :
Odds Ratio(OR) 1.32 (95%
CI 0.28, 6.24) comparing
top quartile (25.0–66.8
µg/m3) to bottom quartile
(0.0–25.0 µg/m3)
[29]
São José dos
Campos,
Brazil
2010–2011 Time-seriesstudy
Daily hospital
admissions in
elderly people (60
years and above)
1765
Gent Stacked Filter-like
sampler; Companhia
Ambiental do Estado de
São Paulo—CETESB
monitoring station
4.4 5 days (350 days)
CVD hospital
admissions
(Health Services
Information
Database)
Every 10 µg/m3 increase
in PM2.5 increased the
risk of CVD
hospitalization by 19.6%
(95% CI 6.4, 34.6)
[30]
Six cities of
the Pearl
River Delta
region,
China
2013–2015 Cross-sectionalsurvey Deaths registered 316,305
Monitoring stations in
each of the six cities:
Guangzhou, Shenzhen,
Zhuhai, Dongguan,
Foshan, and Jiangmen
35.1 to
47.9 4 days (886 days)
CVD Mortality
(Guangdong
Provincial Center
for Disease
Control and
Prevention)
Every 10 µg/m3 increase
in PM2.5 concentration
was associated with
2.19% (95% CI 1.80, 2.59)
increase in CVD mortality
[31] Guangzhou,China 2007–2011
Time-series
study
General
population 33,721
Panyu Meteorological
Center, South China
Institute of
Environmental Sciences
& GRIMM Aerosol
Spectrometer
41.4 4 days (1079 days)
CVD mortality
(Guangdong
Provincial Center
for Disease
Control and
Prevention)
An inter-quartile range
(IQR) increase in PM2.5
(31.5 µg/m3) was
associated with excess
risk of CVD mortality by
6.11% (95% CI 1.76, 10.64)
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Table 1. Cont.
Citation Place ofStudy
Study
Period Study Design
Study Population
(Age, Gender) Sample Size
Particulate Matter
Measuring Less Than
2.5 µm (PM2.5)
Measurement
Method
Mean
PM2.5
µg/m3
Exposure
Association to
Outcome
(No. of Days
Exposure Data-
Available)
Outcomes
(Source) Results
[32] Beijing,China 2004–2006
Time-series
study
Emergency room
visits (ERV) 13,026
Twin Differential
Mobility Particle Sizer
and Aerodynamic
Particle Sizer
109.8 11 days (1035days)
CVD ERV
(Emergency
Department of
Hospital)
An IQR increase in PM2.5
(43.0 µg/m3) was
associated with 0.3% (95%
CI (-)2.4, 3.0) and (-)0.1
(95% CI 3.4, 3.3) total and
severe CVD ERV,
respectively
[33] Beijing,China 2008–2011
Time-stratified
case-crossover
study
Death registered 145,477 U.S. embassy 95.7 40 days (1046days)
CVD/
Cerebrovascular
disease
(CBD)/Ischemic
Heart Disease
(IHD) (Death
Registry of
Chinese Center for
Disease Control
and Prevention)
Every 10 µg/m3 increase
in PM2.5 was associated
with an increased risk of
CVD mortality of 0.24%
(95% CI 0.11, 0.39), CBD
mortality of 0.23% (95%
CI 0.03, 0.42), and IHD
mortality of 0.22% (95%
CI 0.12, 0.54)
[34]
São José do
Rio Preto,
Brazil
2011–2012 Time-seriesstudy
Hospitalizations
registered 4505
Coupled Chemistry
Aerosol-Tracer
Transport model to the
Brazilian
developments on the
Regional Atmospheric
Modeling System
(CCATT BRAMS
model)
23.8 5 days (365 days)
CVD
hospitalization
(Unified Health
System)
Every 10 µg/m3 increase
in PM2.5 was associated
with a 15% increased
relative risk (RR) for CVD
hospitalization with SE of
0.007%
[35] Shenyang,China 2006–2008
Time-series
study
General
population 32
Continuous monitoring
system at Shenyang
Regional
Meteorological Center;
Ambient Dust Monitor
365
95.9 3 days (730 days)
Cause specific
mortality
(Liaoning
Provincial Center
for Disease
Control and
Prevention)
Every 10 µg/m3 increase
in PM2.5 was associated
with a 0.42% (95% CI 0.10,
0.73) increase in CVD
mortality
[36]
Cuiabá and
Várzea
Grande,
State of
Mato Grosso,
Brazil
2009–2011 Time-seriesstudy
General
population aged
45 years and
above
8610
hospitalizations
and 3024
deaths
Method developed and
validated for the
Brazilian Amazon and
Cerrado
17.7 10 days (983 days)
Daily mortality
and
hospitalization
(Mortality
Information
System and
Hospital
Information
System)
Every 10 µg/m3 increase
in PM2.5 was associated
with a 2.64% (95% CI 0.53,
4.06) increase in risk of
CVD hospitalizations and
3.57% (95% CI 0.82, 6.38)
increase in CVD mortality
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Table 1. Cont.
Citation Place ofStudy
Study
Period Study Design
Study Population
(Age, Gender) Sample Size
Particulate Matter
Measuring Less Than
2.5 µm (PM2.5)
Measurement
Method
Mean
PM2.5
µg/m3
Exposure
Association to
Outcome
(No. of Days
Exposure Data-
Available)
Outcomes
(Source) Results
[37] Chongqing,China 1995
Cross-sectional
survey Deaths registered 47
24-hour samples
collected from two
roadside sites from
representative areas of
differing principal
social activities
147 5 days (213 days)
Daily mortality
(Chongqing
Anti-Epidemic
Station)
Every 100 µg/m3 increase
in PM2.5 was associated
with 1.09% (95% CI
0.95,1.20) increase in CVD
mortality
CI-confidence interval; CVD-cardiovascular disease; PM-Particulate matter; NA-not available; T2DM-type 2 diabetes mellitus; OR-odds ratio; IQR-inter-quartile range; IHD-ishcemic heart
disease; CBD-cerebrovascular disease; RR-relative risk.
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Table 2. Study characteristics, exposure, outcome, and primary results of included studies (n = 6, listed alphabetically) measuring PM2.5 exposure as annual average
or more.
Citation Place of Study StudyPeriod Study Design
Study
Population
(Age, Gender)
Sample
Size
PM2.5
Measurement
Method
Mean
PM2.5
µg/m3
Exposure
Association to
Outcome
(No. of Days
Exposure
Data-Available)
Outcomes (Source) Results
[38] Varanasi, India 2001–2015 Time-seriesstudy
General
population 5700
MODIS onboard
NASA-EOS AQUA
and TERRA satellites
136.9 13 years (13 years)
Premature mortality
from ischemic heart
disease (IHD),
Stroke (Premature
deaths)
The estimated premature
deaths per year from
ambient PM2.5
exposure in Varanasi:
IHD 1600 (95% CI 600,
2200), Stroke 1000 (95%
CI 500, 1400)
[39]
Shanghai and seven
provinces of
Guangdong, Hubei,
Jilin, Shaanxi,
Shandong, Yunnan,
and Zhejiang, China
2007–2010 Cross-sectionalsurvey
General
population
aged 50 years
and above
12,665
van Donkelaar and
co-workers to
estimate the outdoor
PM2.5 concentrations
33.7 3 years (3 years)
Hypertension
(World Health
Organistion (WHO)
Study on global
aging and adult
health)
Odds ratio (OR) for
hypertension: 1.14 (95%
CI 1.07, 1.22) for every 10
µg/m3 increase in PM2.5
[40] National, China 2011–2012 Cross-sectionalsurvey
General
population
aged ≥45
years
11,847 Satellite-based spatialstatistical model 72.6 1 year (303 days)
Type 2 diabetes
mellitus (T2DM)
prevalence, blood
glucose, and
HemoglobinA1c
(HbA1c) (survey)
An inter-quartile range
(IQR) increase in PM2.5
(41.1 µg/m3) was
associated with increased
T2DM prevalence ratio(
PR)1.14 (95% CI 1.08,
1.20), elevated levels of
fasting glucose by 0.26
mmol/L (95% CI 0.19,
0.32), and HbA1c by
0.08% (95% CI 0.06, 0.10)
[41] National, China 2015 Cross-sectionalsurvey
General
population
aged 20–49
years
10,843,140
Hybrid geophysical
statistical
approach
47.1 3 years (3 years)
Tachycardia and
Resting heart rate
(Survey)
OR for tachycardia: 1.018
(95% CI 1.017, 1.020) and
a 0.076 (95% CI 0.073,
0.079) bpm elevation in
the resting heart rate for
every 10 µg/m3 increase
in PM2.5
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Table 2. Cont.
Citation Place of Study StudyPeriod Study Design
Study
Population
(Age, Gender)
Sample
Size
PM2.5
Measurement
Method
Mean
PM2.5
µg/m3
Exposure
Association to
Outcome
(No. of Days
Exposure
Data-Available)
Outcomes (Source) Results
[42] Liaoning, China 2009 Cross-sectionalsurvey
General
population
aged 18–74
years
15,477 Satellite-based spatialstatistical model 82.0 3 years (3 years)
Prevalence of
diabetes, fasting
glucose, 2-hour
glucose, and 2-hour
insulin (Survey)
An IQR increase in PM2.5
(26 µg/m3) was
significantly associated
with increased diabetes:
OR 1.14 (95% CI 1.03,
1.25)
[43] National, China 2000–2005 Cohort study Males 40 yearsand above 189,793
Combination of
satellite-derived and
chemical transport
model estimates
calibrated to surface
measurements
43.7 6 years (6 years) CVD Mortality(Survey)
Hazard ratio (HR) for
CVD mortality was 1.09
(95% CI 1.08, 1.10) for
every 10 µg/m3 increase
in PM2.5
CBD-Cerebrovascular Disease; CI-Confidence Interval; CVD-Cardiovascular Diseases; DBP-Diastolic Blood Pressure; T2DM-Type 2 Diabetes Mellitus; ER-Excess Risk; ERV-Emergency
Room Visits; HbA1c-HemoglobinA1c; HR-Hazard Ratio; IHD-Ischemic Heart Disease; IQR-Interquartile Range; OR-Odds Ratio; PM-Particulate Matter; PR-Prevalence ratio; RR-Relative
Risk; SBP-Systolic Blood Pressure.
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The following study designs were used in the included studies: seven were cross-sectional studies,
eight were time-series studies, one was a time-stratified case-crossover study, and one was a cohort
study. The included studies were conducted in the following countries: Brazil (n = 3), Bulgaria (n = 1),
China (n = 11), India (n = 1), and Mexico (n = 1). Only two studies were conducted before 2008, and
the rest were conducted after 2008 (past 10 years) on the studied outcomes.
4.2. Study Characteristics: Exposure and Outcomes
The most common methods of exposure assessment used in these studies were modeled estimates
from hybrid space-time models, which use a combination of satellite remote sensing, meteorology, and
land use as predictors (n = 8); data from nearby monitoring stations (n = 4); both direct measurements
of PM2.5 and data from monitoring stations (n = 3) and direct measurement using personal monitors
(n = 2). We could not perform meta-analyses due to the heterogeneity of PM2.5 measurement methods
across studies. The average concentration of PM2.5 reported in all of the Chinese studies was 73.85
µg/m3 ranging from 33.7 µg/m3 to 147 µg/m3. PM2.5 concentrations reported by studies conducted in
India (2015), Brazil (2010–2012), Bulgaria (2014), and Mexico (1995) were 136.9 µg/m3, 4.4 to 23.8 µg/m3,
66.8 µg/m3, and 27 µg/m3, respectively. With respect to CMD outcomes reported in the included studies,
three studies evaluated hospital admissions and emergency room visits (ERV); nine studies evaluated
CVD mortality; five studies evaluated CVD risk factors, including T2DM. Table 1 summarizes 11 studies
which evaluated shorter PM2.5 exposure windows (3 days up to 40 days), and Table 2 summarizes
six studies which evaluated longer PM2.5 exposure windows (annual average up to 13-year average).
The exposure association to outcome grouped the included studies into two categories, namely studies
measuring less than annual averages of exposure and studies measuring an annual average of exposure
with an exact number of days of exposure assessment mentioned in the Tables 1 and 2.
4.3. Mortality Outcomes
Of the nine studies that evaluated CVD mortality [27,31,33,35–38,43,44], eight (91%) reported
significant effects of long-term PM2.5 exposure. Of these studies, six were conducted in China, and one
study each was carried out in Mexico, India, and Brazil. For every 10 µg/m3 increase in PM2.5, CVD
mortality increased, ranging from 0.24% (95% CI 0.05, 0.43) on 40th day after exposure to 6.11% (95% CI
1.76, 10.64) per interquartile (IQR) increase (31.5 µg/m3) in PM2.5 at moving averages for the previous 3
days [31,33].
The national prospective cohort study conducted in China, which included 189,793 men aged 40
years and above, reported a hazard ratio (HR) for CVD mortality for every 10 µg/m3 increase in PM2.5
of 1.09 (95% CI 1.08, 1.10) for a 6-year time period [43]. A time-series study from Guangzhou with a
sample size of 33,721 adults reported that the excess risk (ER) of CVD mortality was 6.11% (95% CI 1.76,
10.64) per IQR increase in PM2.5 at moving averages for the previous 3 days [31]. A study of 145,477
adults aged 45 years and above conducted in Beijing reported the estimated percentage increase in the
risk of death for every 10 µg/m3 increase in PM2.5. They found that the risk of CVD mortality rose
by 0.24% (95% CI 0.05, 0.43), cerebrovascular disease (CBD) mortality by 0.23% (95% CI (-)0.03, 0.50),
and ischemic heart disease (IHD) mortality by 0.22% (95% CI 0.06, 0.50) over 0–5 days [33]. For every
10 µg/m3 increase in PM2.5, a study in Shenyang, China found an increase in CVD mortality of 0.42%
(95% CI 0.10, 0.73) [35]. In contrast, a study conducted in Chongqing, China found no association
between CVD mortality and PM2.5 [37].
The only Mexican study reported that for every 10 µg/m3 increase in PM2.5, there was a 3.4% (95%
CI 0.67, 6.18) increase in CVD mortality [27]. The only study from India reported a burden of 5700
(95% CI 2800, 7500) annual premature deaths (0.16% of the population) attributable to PM2.5 exposure,
of which 29% and 18% were IHD and stroke, respectively. The estimated premature deaths per year
from ambient PM2.5 exposure in Varanasi, India by IHD was 1600 (95% CI 600, 2200) and stroke was
1000 (95% CI 500, 1400) [38]. A Brazilian study reported that every 10 µg/m3 increase in PM2.5 resulted
in a relative risk (RR) of 1.81% (95% CI 0.03, 3.61) for CVD mortality [36].
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4.4. Hospital Admissions and Emergency Room Visits
There were four studies [29,32,34,36], one from China and three from Brazil that evaluated hospital
admissions and ERV. All reported significant effects of long-term PM2.5 exposure.
In Brazil, the RR was 2.64 (95% CI 1.60, 3.69) for hospitalizations related to PM2.5 over a period
of 10 days [36]. Another study in Brazil reported a significant increase in the risk of hospitalization
for circulatory system diseases of 19.6% (95% CI 6.4, 34.6) per 10 µg/m3 increase in PM2.5 5 days after
exposure [29]. The third study in Brazil similarly reported a 15% (SE 0.07%) increase in the risk of
hospitalization for CVD per 10 µg/m3 increase in PM2.5 concentration 5 days after exposure [34].
The only Chinese study found that an IQR increase in PM2.5 (43.0 µg/m3) was associated with
0.3% (95% CI (-)2.4, 3.0) total CVD ERV for 11-day moving average [32].
4.5. CVD Risk Factors
Of the five studies that evaluated CVD risk factors [28,39–42], including T2DM, all reported
significant effects of long-term PM2.5 exposure. Four of these studies were conducted in China, and one
study was conducted in Bulgaria. The following CVD risk factors were assessed by studies included in
this review: hypertension (n = 1), tachycardia and resting heart rate (n = 1), insulin resistance and
T2DM (n = 3).
A study conducted in China among adults aged 50 years and above found that for every 10 µg/m3
increase in PM2.5 over a 3-year period, the adjusted OR for hypertension was 1.14 (95% CI 1.07, 1.22).
Each 10 µg/m3 increase in ambient PM2.5 was associated with a 1.04 mmHg (95% CI 0.31, 1.78) increase
in diastolic blood pressure and a 1.30 mmHg (95% CI 0.04, 3.56) increase in systolic blood pressure [39].
A cross-sectional survey among adults between 20 and 49 years, also from China over a 3-year period,
reported, for every 10 µg/m3 increase in PM2.5, that the OR for tachycardia was 1.018 (95% CI 1.017,
1.020) and resting heart rate increased by 0.076 bpm (95% CI 0.073, 0.079) [41]. Another Chinese study
found that PM2.5 was significantly associated with increased diabetes by OR: 1.14 (95% CI 1.03, 1.25)
per IQR increase (26 µg/m3) in PM2.5 over a 3-year period [42].
A study in China among adults aged 45 years and above reported that an annual average IQR
increase (41.1 µg/m3) in PM2.5 was significantly associated with increased T2DM prevalence, PR= 1.14
(95% CI 1.08, 1.20), elevated levels of fasting glucose by 0.26 mmol/L (95% CI 0.19, 0.32), and elevated
HbA1c by 0.08% (95% CI 0.06, 0.10) [40]. A study from Bulgaria reported that PM2.5 was positively
associated with T2DM, OR 1.32 (95% CI 0.28, 6.24) [28].
5. Discussion
We identified just 17 studies conducted in LMICs with the link between long-term PM2.5 exposure
and CMD, and most of the studies (65% of studies) were in China. This is concerning because LMICs
carry the greatest burden of both CMD and air pollution, and most of the studies we reviewed reported
significant increases in CVD mortality with increasing PM2.5 levels. The Global Burden of Disease
(GBD) in 2015 and Global Health observatory data repository reported that the population-weighted
mean exposure to PM2.5 in China, India, Brazil, Mexico, and Bulgaria were 58.4 µg/m3 (95% CI 58.1,
58.7), 74.3 µg/m3 (95% CI 73.9, 74.8), 11.4 µg/m3 (95% CI 11.2, 11.5), 20.1 µg/m3 (95% CI 16.7, 27.2),
and 18.8 µg/m3 (95% CI 18.3, 20.6), respectively. In our review, all the included studies indicated
higher levels of PM2.5 than reported by the GBD except for one study from Brazil [29], which reported
slightly lower estimates. In this review, PM2.5 estimates reported by Chinese studies ranged from
33.7 to 147 µg/m3; Indian PM2.5 estimates ranged from 94.4 to 136.9 µg/m3; Brazilian PM2.5 estimates
ranged from 4.4 to 23.8 µg/m3; Mexican PM2.5 estimates was 27.0 µg/m3, and Bulgarian study reported
66.8 µg/m3, all of which were much higher than the values reported by the GBD study [4]. Therefore,
the GBD estimates may be underestimating CVD deaths attributable to PM2.5 in the countries of focus.
Similarly, a global review and meta-regression analysis also observed much lower levels of PM2.5 in
China compared to our estimates [45]. Most (70%) of the research studies included in this review were
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conducted in major cities and industrial centers in China, including Beijing, Chongqing, Guangzhou,
Liaoning, Pearl River Delta region, Shanghai, and Shenyang, which may at least partially explain this
deviance from the GBD estimates. Satellite-based estimates must be used cautiously and following
shortcomings must be kept in mind: underestimation of ground measurements in locations with higher
concentrations like East Asia, South Asia, North Africa, and Sub-Saharan Africa [46].
The duration of exposure ascertainment to outcome varied from a 3-day average to a 13-year
average. The effect estimates varied with duration of exposure- longer exposure periods associated
with smaller effect estimates. We observed differences among the effect estimates for cardiovascular
mortality for annual averages or longer duration and less than annual averages. In our review,
we observed that the effect estimates were smaller when the exposure window was longer, which
needs further investigation. This was similar to a global meta-analysis of cohort studies, which also
found that the effect estimates decreased with increasing concentrations [45].
This review was focused on CMDs as we currently lack literature on the effects of long-term
exposure to PM2.5 on CMDs in LMIC settings. Globally, 17.1% of IHD mortality and 14.2% of CBD
mortality in 2015 was attributable to PM2.5 as reported by GBD [7]. A prospective European cohort
study found an increased risk of stroke associated with a 5 µg/m3 increase in PM2.5 with a hazard ratio
of 1.19 (95% CI 0.88, 1.62) [13]. In our review, Luo et al. from their Beijing study reported that every
10 µg/m3 increase in PM2.5 was associated with an increased risk of CBD mortality of 0.23% (95% CI
(-)0.03, 0.50) [33].
Across all of the included studies, the results ranged from 0.24% [33] to 6.11% [31] increase in
CVD mortality for every 10 µg/m3 increase in PM2.5. While this effect estimate is relatively small,
the ubiquitous nature of the exposure is likely to result in a large population-attributable disease
burden. This range of values was higher than a recent meta-regression analysis of 53 studies, that
found the percent increase at mean exposure of 10 µg/m3 PM2.5 associated with a 1.46% (95% CI
1.25, 1.67) increase in CVD mortality [45]. Similarly, a review of European epidemiological studies
reported that the relative risk of CVD mortality was 1.11 (95% CI 1.07, 1.15) for a quartile increase in
PM2.5 [47]. Another global review also noted that cardiorespiratory mortality was increased by 2.29%
(95% CI 1.36, 3.85) per 10 µg/m3 increase in PM2.5 [48]. The effect estimates depended on the type of
exposure assessment method as using ground-level monitors produced estimates 44–46% lower than
that of hybrid space-time model [45]. Most of the studies reviewed here utilized secondary data from
stationary monitoring stations (seven studies) or were modeled estimates (eight studies), which might
not accurately reflect personal exposures. The only Indian study reported that premature mortality per
year in the city of Varanasi from IHD was 1600 (95% CI 600, 2200) and stroke was 1000 (95% CI 500,
1400) after exposure to PM2.5 that could be saved [38]. There were no Indian studies measuring the
impact of ambient air pollution on cardio-metabolic health outcomes, which needs focus in the future
studies, given the fact that air pollution levels are alarmingly high, especially in the Indo-Gangetic
plain [49].
A strong association between PM2.5 and CVD hospital admissions was observed. A pooled
estimate from European countries reported that relative risk of cardiovascular hospitalizations increased
by 1.8% (95% CI 0.1, 3.4) per IQR increase in PM2.5 (12.4 µg/m3) [50]. Results from a global review and
meta-analysis showed that hospital admissions due to cardiorespiratory diseases were increased by
1.64% (95% CI 1.06, 2.53) per 10 µg/m3 increase in PM2.5 [48], which was much lower than the studies
from Brazil identified in this review that reported a 15–19.6% increase in CVD hospitalizations [29,34].
On the contrary, a Chinese study observed that total and severe CVD ERVs increased by 0.3% (95%
CI (-)2.4, 3.0) and decreased by 0.1% (95% CI 3.4, 3.3) for an IQR increase in PM2.5 by 43.0 µg/m3 in
11-day moving average, respectively, which indicated delayed association [32]. The varying effect
estimates could be attributed to the population included and the exposure assessment method used in
these studies.
Long-term exposure showed the strongest associations with hypertension. In a meta-analysis,
there was a statistically insignificant increase in hypertension risk (OR = 1.065, 95% CI 0.985–1.152)
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with each 10 µg/m3 increment in PM2.5 [17]. We found very similar results from the Chinese study by
Lin et al. who reported an increased risk of hypertension by an OR = 1.14 (95% CI 1.07, 1.22) with
each 10 µg/m3 increment in PM2.5 [39]. A meta-analysis among cohort studies reported a positive
association for T2DM and relative risk of 1.25 (95% CI 1.10, 1.43) for every 10 µg/m3 increase in
PM2.5. Another review of European and North American studies reported that the pooled relative
risk estimate for T2DM per 10 µg/m3 increase in PM2.5 was 1.10 (95% CI 1.02, 1.18) [15]. The Chinese
study from our review reported that for an IQR increase in PM2.5, T2DM prevalence increased by
PR = 1.14 (95% CI 1.08, 1.20) [40]. There were no studies conducted on lipid disorders with respect to
air pollution exposure.
In this review, about two-thirds of the studies included were conducted in the last three years
(2016–2018) indicating that this area is gaining more focus recently. A prospective cohort study design
is considered the gold standard, but only one study, which was conducted in China, used a cohort
design [43]. Further studies examining personal exposure to PM2.5 or statistically modeled estimates
for PM2.5 and CMDs in LMICs are in urgent need to help develop scientific literature.
This study is not without its limitations, firstly the heterogeneity of identified studies prohibited
the use of meta-analytical methods to produce summary estimates of effect. We focused on long-term
exposures considering that in LMICs, ambient air pollution is chronic exposure and effects may be larger
for long-term exposures versus short-term exposures. From our review results, we cannot conclude
this assumption, as we found that for a longer duration of exposure, the effect estimates were smaller,
and further investigation is needed to confirm this. The second limitation is that we focused solely
on one component of ambient air pollution, PM2.5, yet individuals are exposed to complex mixtures.
We chose to focus on PM2.5 versus PM10 because previous research has demonstrated a stronger effect
on CVD due to the ability of PM2.5 particles to travel to distant organs [14]. Moreover, most included
studies used a single-pollutant model, but a few also measured other pollutants, including PM10, PM1,
sulfur dioxide (SO2), nitrogen dioxide (NO2), nitrous oxide (NO), carbon monoxide (CO), ozone (O3),
black carbon, organic and elemental carbon, soluble ions, and noise and traffic pollution. We evaluated
only the effect estimates of PM2.5 here. The third limitation is the type of studies included in this
review is very different and, hence, the effect sizes should be interpreted with caution. Future research
should expand to include multipollutant models that take into account potential interactions between
pollutants, as well as source-specific effects.
In conclusion, few studies have evaluated the association between long-term exposure to PM2.5
and CMD outcomes in LMICs, and the majority of this literature has come from China. We did not
identify a single study conducted in North and Sub-Saharan Africa, which is home to 17% of the
world’s population. Considering that the vast majority of morbidity and mortality attributable to
PM2.5 is in LMICs, this represents a major environmental injustice. The global environmental health
community must drive a strong research agenda relating to the CMD effects of PM2.5 in these settings
in order to provide context-specific evidence to policymakers in these countries.
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CBD-Cerebrovascular Disease;
CI-Confidence Interval;
CMD-Cardio-Metabolic Diseases;
CO-Carbon Monoxide;
CVD-Cardiovascular Diseases;
DBP-Diastolic Blood Pressure;
DM/T2DM-Diabetes Mellitus/Type 2 Diabetes Mellitus;
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HbA1c-HemoglobinA1c;
HIC-High Income Countries;
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IHD-Ischemic Heart Disease;
IQR-Interquartile Range;
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O3-Ozone; OR-Odds Ratio;
PM-Particulate Matter;
RR-Relative Risk;
SBP-Systolic Blood Pressure;
SD-Standard Deviation;
SO2-Sulfur Dioxide;
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Appendix A.
Appendix A.1. Search Terms
Air pollution: "air pollution" or "particulate matter" or "air pollutants" or "ambient air pollution" or "Total
suspended particles" or "particulate matter" or "soot"
CMD: "diabetes" or "diabet*" or "IDDM" or "NIDDM" or "Cardiovascular*" or "Cardiovascular Diseases"
or "Cardiovascular Abnormalities" or "Heart Arrest" or "Cardiac arrest*" or "Arterial Occlusive Diseases" or
"Cerebrovascular Disorders" or "Hypertens*" or "Myocardial Ischemia" or "Prehypertens*" or "Angina*" or "Glucose
Metabolism Disorders" or "Diabetes*" or "Prediabet*" or "Hyperglycem*" or "Glucose Intoleran*" or "Insulin
Resistan*" or "Lipoprotein*" or "Apolipoprotein*" or "Chylomicrons" or "Chylomicron Remnants" or "Cholesterol*"
or "High-Density Lipoproteins, Pre-beta" or "Cardiac Death" or "Asphyxia" or "Brain Death" or "Death, Sudden" or
"Death, Sudden, Cardiac" or "Sudden Cardiac Death" or "Sudden Cardiac Arrest" or "Cardiac Arrest, Sudden"
Countries: Low- and Middle- Income Countries (Low income, lower middle income, upper middle-income
countries) and “NOT” High Income Countries (see Table A1 for detailed search strategy).
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Appendix A.2. Cochrane Risk of Bias Tool
Table A1. Low risk of bias.
Study Title Selection Exposure Assessment Confounders Outcome Assessment
1 Borja-Aburto 1998
2 Dzhambov 2016
3 Ferreira 2016
4 Jain 2017
5 Lin 2016
6 Lin 2016
7 Lin 2017
8 Liu 2013
9 Liu 2016
10 Luo 2016
11 Mantovani 2016
12 Meng 2013
13 Rodrigues 2017
14 Venners 2003
15 Xie 2018
16 Yang 2018
17 Yin 2017
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